Alaeddin Ali Maeza

Alaeddin Maeza practices at UW Health SwedishAmerican Hospital in Rockford, Illinois, part of University of Wisconsin Hospitals and Clinics Authority.

Alaeddin Maeza's NPI, 1386937167, was assigned on May 26, 2011. Alaeddin Maeza holds Illinois license 036-150500.

Alaeddin Maeza's primary practice is UW Health SwedishAmerican Hospital, at 1401 East State Street, Rockford, IL 61104 in Winnebago County. The practice phone is (815) 968-4400.

Alaeddin Maeza's primary practice is UW Health SwedishAmerican Hospital in Rockford, Illinois, part of University of Wisconsin Hospitals and Clinics Authority. Alaeddin Maeza is also affiliated with University Hospital. The medical group on file is SwedishAmerican Medical Group. Dmand AI also links Alaeddin Maeza to 1 more hospital and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Alaeddin Maeza practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Alaeddin Maeza's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Alaeddin Maeza's licenses on file in 2 states: Illinois and Michigan.

CMS data shows 1,539 Medicare services from Alaeddin Maeza across 12 procedure codes in 2024, for 337 Medicare patients. Medicare paid $74,417 for them.

CMS counts 337 Medicare patients who saw Alaeddin Maeza in 2024. The largest group is 65 to 74, with 161 patients. 71% of them have high blood pressure, and 67% have high cholesterol. 22% are also on Medicaid. Their average risk score is 1.89, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Alaeddin Maeza's median patient age at 71, with 50% women.

In 2024, Alaeddin Maeza wrote 1,873 Medicare Part D claims for 314 patients. 81% of them were for generic drugs. CMS names the drug for 1,574 of them, across 52 drugs with 11 or more claims each, at $1,555,210 in total drug cost. In 2023, CMS named 1,813 claims across 51 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 82 out of 100 for Alaeddin Maeza for performance year 2024, reported as part of a group. Alaeddin Maeza accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 17 general payments to Alaeddin Maeza from 8 drug and device companies from 2016 to 2024. Food and beverage make up the largest share, 96% of the total. Merck Sharp & Dohme Corporation paid the most, $112.